Skip to search formSkip to main contentSkip to account menu

VGX-3100

Known as: HPV DNA Plasmids Therapeutic Vaccine VGX-3100 
A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Papillomavirus VaccinesVaccines, DNA

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
ABSTRACT HPV remains the most common sexually transmitted disease worldwide, despite improvements in awareness, screening… 
2017
2017
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Purpose: As previously reported, treatment of high-grade cervical dysplasia with VGX-3100 resulted in complete histopathologic… 
2016
2016
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human… 
Review
2015
Review
2015
HPV Infection of the Head and Neck Region and Its Stem Cells
The human papillomavirus (HPV) is an etiologic agent associated with the development of head and neck squamous carcinoma (HNSCC… 
2015
2015
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and…
Meeting abstracts Oropharyngeal HNSCCa is frequently associated with HPV infection. DNA-based Immunotherapy with plasmids… 
2015
2015
Gynaecological cancer: Therapeutic HPV vaccine holds promise
2014
2014
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind…
The Phase II study, designated HPV-003 (NCT01304524), assessed the safety and efficacy of VGX-3100 in 167 women with biopsy… 
2014
2014
Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial.
3101 Background: Despite the development of highly effective prophylactic vaccines against human papillomavirus (HPV) types 16… 
2012
2012
New vaccine for cervical cancer shows promise
2012
2012
Cervical cancer immunotherapy: Induction of HPV specific CTLs in human volunteers after VGX-3100 immunization
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)